FIG 3.

Relationship between BRAF class and treatment type in the context of MAPK-targeted therapy. (A) Response rates to MAPK-targeted therapy according to BRAF class and treatment type. P values calculated with Fisher's exact test. PFS according to treatment type in the (B) entire cohort, and when analyses are restricted to (C) class 2 and (D) class 3 BRAF-mutant tumors. P values calculated with log-rank test. BRAFi, BRAF inhibitors; EGFRi, EGFR inhibitors; MAPK, mitogen-activated protein kinase; MEKi, MEK inhibitors; PFS, progression-free survival.